Unprecedented Insights
ImaginAb is an emerging immune-oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.
Harnessing the specificity of monoclonal antibodies, ImaginAb designs and engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).
Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.
ACCURACY
INNOVATION
CLARITY
BETTER DATA
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets.
ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent
Collaboration to explore novel radiochemistry manufacture of ImaginAb’s Phase II clinical asset.
ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology
Under the terms of the agreement, ImaginAb’s CD8 ImmunoPET technology will be used in AstraZeneca’s clinical trials in North America and Europe to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET.